Tigermed Calls June EGM to Seek Approval for A-Share Buyback Mandate

An update from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) is now available.

Hangzhou Tigermed Consulting Co., Ltd. has called a second extraordinary general meeting for June 9, 2026, in Hangzhou to seek shareholder approval for a special resolution authorizing the repurchase of its A shares via centralized price bidding. The proposal covers key parameters such as the purpose, scale, pricing range, funding source and duration of the buyback, as well as a mandate for management to handle implementation details.

The company will put both A and H share investors to a poll as a single class, with H share registration closing from June 4 to June 9 to determine eligibility to vote. Shareholders may appoint proxies subject to formal procedures, and the buyback resolution will require a two-thirds majority, signaling a potentially significant capital management move that could influence share liquidity and capital structure for existing investors.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

More about Hangzhou Tigermed Consulting Co., Ltd. Class H

Hangzhou Tigermed Consulting Co., Ltd. is a China-based contract research organization serving the pharmaceutical and biotech industries, providing clinical research and related consulting services. The company is listed in Hong Kong as a Class H share issuer and operates across both A Share and H Share markets, reflecting a focus on global capital access and diversified investor participation.

Average Trading Volume: 1,802,608

Technical Sentiment Signal: Sell

Current Market Cap: HK$40.7B

Find detailed analytics on 3347 stock on TipRanks’ Stock Analysis page.